LB-102

Schizophrenia

Manufacturer: LB Pharmaceuticals Inc
Regulatory submission: Not announced
Launch: Not announced
Last updated: October 8, 2026

Section

Product information and disease description Product description

Product information

236 evidence topics · 119 sources

Generic, brand name and therapeutic class of product3 evidence topics · 5 sources
Dosage forms and strengths6 evidence topics · 7 sources
American hospital formulary service (AHFS), or other drug classification2 evidence topics · 3 sources
Indication4 evidence topics · 4 sources
Pharmacology36 evidence topics · 20 sources
Contraindications/Warnings/Precautions/Adverse effects17 evidence topics · 10 sources
Special populations15 evidence topics · 9 sources
Drug/Drug, drug/disease interactions9 evidence topics · 5 sources
Dosing and administration16 evidence topics · 12 sources
Access and distribution6 evidence topics · 4 sources
Co-prescribed/Concomitant therapies10 evidence topics · 4 sources
Effect of LB-102 on quality measures18 evidence topics · 17 sources
Product comparison94 evidence topics · 73 sources

Average sales price and wholesale acquisition cost

Product price and anticipated annual cost of treatment

Not applicable.